Marker Therapeutics, Inc.

MRKR Nasdaq SEC CIK 1094038
Follow Marker Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$1.8M +7.7% vs same quarter last year
EPS, diluted −$0.10 +16.7% vs same quarter last year
Operating cash flow −$2.5M +8.8% vs same quarter last year
Operating income −$3.2M +4.2% vs same quarter last year
Revenue by quarter
$2.3M
$349.1K
$861.2K
$1.2M
$1.1M
$751.7K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$3.5M−$12.2M
FY24$6.6M−$10.7M
FY23$3.3M−$8.2M
FY22$3.5M−$29.9M
FY21$0−$41.9M
FY20$500K−$28.7M
FY19$213.2K−$21.4M
FY18$206K−$148M
FY17$183.1K−$11M
FY16-−$2.5M
FY15-−$34.1M
FY14-−$30.9M
FY13-−$5.5M
FY12-−$5.9M
FY11-−$2M
MarginsShare of revenue
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−363.5%−343%
FY24−168.7%−162.8%
FY23−440.4%−248.8%
FY22−563.3%−851.9%
FY21--
FY20−5777.2%−5741.2%
FY19−10567.3%−10050.9%
FY18−71930.1%−71826.3%
FY17−6271.1%−5999.1%
FY16--
FY15--
FY14--
FY13--
FY12--
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19−$18.7M
FY18−$14.6M
FY17−$8.4M
FY16-
FY15-
FY14-
FY13-
FY12-
FY11-
Returned to shareholdersDividends paid and shares bought back
$0$100K$200K$300K$400KFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19-
FY18$71.7K
FY17$310.5K
FY16$0
FY15-
FY14-
FY13-
FY12-
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Marker Therapeutics
  • Healthcare median
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearMarker TherapeuticsHealthcare median
FY25−343%−30.6%
FY24−162.8%−47%
FY23−248.8%−58%
FY22−851.9%−80.4%
FY21-−71.9%
FY20−5741.2%−62.2%
FY19−10050.9%−46.3%
FY18−71826.3%−49.6%
FY17−5999.1%−45.9%
FY16-−36%
FY15-−38.4%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%
FY11-−27.9%